Among patients with ACS who undergo PCI, a prasugrel-based strategy is superior to one using ticagrelor in terms of all-cause death, MI, and stroke at 12 months, according to a prespecified ...
PARIS, France—Investigators designing ISAR-REACT 5, the first head-to-head trial of ticagrelor and prasugrel in ACS patients heading for revascularization, expected to prove that ticagrelor is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results